Down-regulation of certain excitatory amino acid transporters (EAATs), such as GLT1, is often reported in various neuropsychiatric diseases such as epilepsy, stroke, AD, depression and movement disorders [3, 4]. Here, SLC1A2 is linked to depressive symptom measurement.